Zinc and AMD.
Recruiting
- Conditions
- AMD, complement, zinc
- Registration Number
- NL-OMON22306
- Lead Sponsor
- Radboud University Nijmegen Medical CentreP.O. Box 9101, 6500 HB NijmegenThe Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1. Men and women ≥ 50 years of age;
2. AMD patients previously included in the EUGENDA database;
Exclusion Criteria
1. Active leakage from CNV due to AMD;
2. Ongoing anti/VEGF treatment;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is the serum level of activation fragment C3d and complement component C3. The C3d/C3 ratio will be calculated. This ratio is the activity marker of the alternative complement pathway.
- Secondary Outcome Measures
Name Time Method The secondary outcome is the correlation between this supposed drop in serum level C3 en C3d and Y402H polymorphism status in CFH.